Alcon unveils Clareon PanOptix Pro in India to expand advanced cataract surgery portfolio

Alcon has announced the launch of Clareon^® PanOptix^® Pro intraocular lens (IOL) for cataract patients in India. PanOptix Pro leverages proprietary ENLIGHTEN^® NXT Optical technology which delivers the lowest light scatter and highest reported light utilisation of any trifocal IOL.

PanOptix Pro provides an unprecedented 94% light utilisation, compared to a theoretical maximum utilisation of 96% for diffractive optics. These enhancements also provide more uninterrupted light distribution from distance to near, and a 16% increase in optical image contrast between distance and intermediate.

PanOptix Pro builds on the clinically-proven low visual disturbance profile, high spectacle independence and exceptionally high patient satisfaction of PanOptix.

“As the global leader in eye care, we are committed to improving our technologies to advance patient outcomes through rigorous, world-class R&D,” said Amar Vyas, Country Head, Alcon India. “Our team looked at hundreds of design options, ultimately landing on a targeted diffractive refinement that helped us recover 50% of light lost to scatter, and reposition it to a beneficial focal point for PanOptix Pro. This allowed for specific enhancements while maintaining the features that have driven the success of PanOptix—the world’s most implanted trifocal IOL.”